At the nexus of high-end organic food and the kind of healthy play-focused indoor child playground accommodations, like the ones you can find at Gymboree Play and Music recreation centers, is a new brand of upscale, family-friendly adult restaurant and child play centers that well-known celebrities in the Los Angeles area are flocking to with their families. It is not uncommon to see the likes of Adam Sandler, Dustin Hoffman, Jessica Alba, or Ben Affleck and Jennifer Garner taking their children to one of the Giggles N’ Hugs, Inc. (OTC: GIGL) locations in Los Angeles, driven by the superb services, eye-popping decor, wonderful food, and extremely well-thought-out amenities.

With features like affordable packages for families that allow them to treat their children to one-of-a-kind themed birthday parties, where the award-winning Giggles N’ Hugs staff of professionals takes care of every detail, bringing kids the most exciting party of their young lives, full of games, prizes, costumed characters, toy bundles and scrumptious food, this rapidly emerging chain of restaurants has won fast favor with parents and kids alike. Named the number one birthday party destination in Los Angeles by popular kids network Nickelodeon, Giggles N’ Hugs offers parents healthy, delicious organic menu options, while keeping the young ones busy with exercise, events like puppet shows and music, as well as custom-built indoor play areas (approximately 2,000 square feet or more) that are something out of a child’s wildest dream, attended by trained GIGL staff.

From ball pits, climbers and swings, to castles, pirate ships and dragons, the lovingly crafted play areas at Giggles N’ Hugs locations are truly a sight to behold. Located in upscale malls and neighborhoods in Century City, Glendale and Topanga, these gorgeous locations are perfect for events, like a wide variety of themed birthday parties for boys or girls, with fully decorated and catered themes such as dinosaurs, superheroes, pirates and mermaids, princesses, rock stars and others available upon request.

Open on weekdays from 10:30am to 8pm (9pm on Fridays), as well as on weekends from 10am to 7pm (9pm on Saturdays), and featuring $11 per child admission for all day play, Giggles N’ Hugs even allows parents to drop their kids off so they can enjoy a relaxing day shopping in the mall or at nearby businesses, content in the knowledge that their child is safe and enjoying active play under the watchful eye of the company’s trained staff. Giggles N’ Hugs even caters meetings, office parties and other events, offering the same great menu that is available in the restaurant – featuring appetizers, sandwiches, wraps and paninis, as well as salads, pizzas and pasta dishes – providing all the staff and planning required. This full-spectrum, customer-first business model, wrapped around an innovative formula that appeals directly to health-conscious consumers who want someplace their children can enjoy healthy exercise, play and engaging activities, meets an underserved, and in most regions unserved demographic.

Investors might be tempted to write off this still-emerging model as a high-end, boutique Chuck E. Cheese, but GIGL has some serious national as well as international expansion potential. The company has already clearly defined an entirely novel model for this industry segment, and one which taps into a demographic that is not being serviced by any other player in quite the same way.

With strong, expressed interest from franchisees throughout North America, as well as in Asia, Australia, Europe, Latin American and the Middle East, such long-term growth potential underwriting the company’s already masterful execution of its core model at the existing company-owned locations should be quite tantalizing to market participants. With potential franchise margins in excess of 25 percent and multi-unit licensing fees ranging from several hundred thousand, to millions of dollars, even as ongoing royalties range from 3 percent to 8 percent of gross sales, Giggles N’ Hugs could rapidly ramp up nationally and globally, capturing the growing global demand for high-quality food and someplace to take, or drop off, the kids.

First mover advantage with a proven model that is quickly hammering out its own market niche, solid resonance with consumers, and a sumptuous menu of quality organic dishes all spell a very bright future for GIGL and its shareholders.

Learn more by visiting www.gigglesnhugs.com/investor-relations/

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

Fastfunds Financial is focused on building a portfolio of revenue-generating companies that provide ancillary services to the burgeoning cannabis industry in varying capacities. FFFC’s overarching execution strategy is to deepen its position in the industry by advancing the development several separate business verticals.

FFFC’s current suite of companies consists of two wholly owned subsidiaries: Cannabis Angel, Inc. (CA) and The 420 Development Corporation; as well as majority-owned subsidiary Financiera Moderna, Inc., which offers financial services to the underserved Hispanic community. FFFC also has a 49% stake in Cannabis Merchant Financial Solutions, Inc. (CMFS), through which FFFC entered the financial service business vertical.

In recent months, much emphasis has been placed on CMFS, the developer of the Green Card and Tommy Chong Green Card, a reloadable stored value card with a rewards feature, and the Tommy Chong Frequent Buyers Card, which functions as a gift card or rewards card. Supporting the continued advancement of CMFS and its growing interest in the financial services market, FFFC is developing a national group of master resellers, distributors and sales representatives for these card products.

The growing cannabis industry is flourishing with ancillary opportunities, among which is plant botany. As the industry continues to develop, FFFC is partaking in the development of methods and technologies to significantly enhance plant growth and purity. Under an operating agreement with Sanidor Systems to create Pure Grow Systems, LLC, FFFC acquired a 49% interest in the subsidiary, which is dedicated to the healthy production and processing of raw materials used for medicinal or other health related purposes.

Though marijuana is legal in 23 states, but illegal at a federal level, banks are wary of participating in the industry. As such, the cannabis industry is a cash-only business, which leaves companies vulnerable to criminal activities.

FFFC’s research shows that operating margins for cannabis-related security services could exceed current billing levels by at least 100%. The company plans to take advantage of this opportunity while addressing cash-only concerns and enter the security services and equipment sector through the acquisition of an existing, operational security company. Complementary to this plan, FFFC also owns a 70% stake in Ohio-based Brawnstone Security, Inc., a diversified security, training and investigations company.

FFFC continues to drop anchors in key segments of the rapidly growing cannabis industry to reduce risk while progressing as a provider of viable solutions in an explosive growth market.

For more information visit www.fastfundsfinancial.com

Let us hear your thoughts: Fastfunds Financial Corp. Message Board

As an engineering and product development company, Galenfeha builds shareholder value by researching new technologies to make certain their customer base is on the leading edge. GLFH is positioned as a technology leader whose industrial position is viewed as integral to the future of their customers’ business goals. Vitally important to the company’s growth is their forward-thinking orientation with respect to being environmentally conscious. Company leadership feels this awareness will continue to grow in importance and help drive success.

The company evaluates projects on a case-by-case basis so that it is certain it blends with their overall mission so that their endeavors are unique and thereby result in truly innovative product and service offerings.

The company’s DLP-S Solar Powered Chemical Injection Pump offers high reliability, simplicity in operation, and efficiency in serviceability. Built from the highest grade 316 SS, it is able to stand up to harsh environments. The multi-purpose pump is comes in a variety of configurations and can be custom matched to specific applications for each customer.
GLFH’s Pneumatic Chemical Injection Pump combines the precision of a solar powered digital control system and the reliability of a pneumatic pump. When combined, it brings both durability and reliability to the forefront of chemical injection technology.

iWAV provides complete control of the customer’s entire chemical injection program. It offers the highest level of return on one of the highest costs involved in operating a well site. Whether communication is radio, cellular, satellite, or direct, the iWAV is ready to meet the needs of operations of all sizes.

Galenfeha, Inc., a development stage company that centers its endeavors on providing engineering services and an alternative power products to natural gas producers. It provides contractual engineering services, develops and manufactures products to reduce its customers cost associated with energy production such as carbon footprint, hazardous waste, and other non-sustainable aspects of producing energy.

For more information on the company, visit www.galenfeha.com

Let us hear your thoughts: Galenfeha, Inc. Message Board

The Aristocrat Group this morning announced that its sponsored artist, budding country music superstar Curtis Braly, this Saturday night will kick off his All About the Ride Tour at Live Nation’s Bayou Music Center in Houston, with all profits benefitting the Lone Survivor Foundation.

Taking place at one of the premiere live-music theaters in North America, the concert is expected to draw thousands of attendees, making it an important event in terms of recognition and exposure for both Braly and ASCC. The event is co-sponsored by ASCC’s RWB Ultra-Premium Handcrafted Vodka and will feature RWB signage and a post-concert VIP party in Bayou Music Center’s Jack Daniel’s Room, where special guests can enjoy ASCC’s highly decorated, American-made vodka.

“This concert is a big moment for Curtis and a big moment for RWB Vodka,” ASCC CEO Robert Federowicz stated in the news release. “It’s a tremendous opportunity to expose Curtis Braly’s hit songs and our ultra-premium vodka to their biggest live audience yet.”

Named the 2014 Country Male Artist of the Year by the International Music and Entertainment Association, Braly has already introduced fans across the U.S. to RWB Vodka by touring the nation’s top country music markets in his RWB-branded tour bus. Earlier this year, Braly represented RWB Vodka at country music’s most important event: the Academy of Country Music Awards at AT&T Stadium in Arlington, Texas.

Handcrafted, American-made RWB Ultra-Premium Handcrafted Vodka is made with the highest-quality, non-GMO Idaho potatoes and pure mountain spring water and then refined by a five-stage filtration system that produces a gluten-free high-class vodka without the high-class price. It is available online to U.S. consumers and at more than 60 retail locations and 250 clubs, bars and restaurants.

For more information visit www.aristocratgroupcorp.com/investors

Let us hear your thoughts: The Aristocrat Group Corp. Message Board

Wisdom Homes of America is on track to reach $4 million in total revenue in its first full year of operation in the manufactured homes industry. In order to promote this milestone, the company is adhering to a detailed growth strategy designed to address limiting issues of the national housing market.

The primary advantage of manufactured homes relates to cost, which is, on average, 60 percent less per square foot than conventional stick-built homes. In the past five years, this price disparity has driven annual industry growth of approximately 10 percent. Last year, domestic manufactured home sales exceeded $4 billion, according to the Manufactured Housing Institute, further demonstrating the tremendous market potential of WOFA’s current business model. In order to capitalize on this growth, WOFA anticipates operating no fewer than 30 retail centers throughout Texas and the surrounding states within the next five years.

In addition to selling homes from its retail centers, WOFA is increasing its market presence by constructing and permanently affixing ‘spec manufactured homes’ in existing subdivisions. Through this strategy, the company is able to eliminate the need for buyers to locate suitable plots of land while simultaneously increasing its margins on each home sold. In the coming weeks, WOFA plans to utilize this strategy to develop a collection of lots in Sherman, TX.

“Our goal as we expand is to position our new retail centers near manufactured home subdivisions and communities and therefore sell into those developments,” Jim Pakulis, chief executive officer of WOFA, stated in a news release. “The model we’ve created in Sherman, TX, creates two revenue streams from the sale of manufactured houses: selling from our soon to open Sherman retail center and selling land-home packages in the Sherman subdivision.”

The company’s final anticipated revenue stream, which it expects to implement by the end of 2015, is an in-house mortgage operation. When in place, this program will enable WOFA to vertically-integrate its clients into its operations, providing an additional source of revenue while bolstering the performance of its retail and subdivision sales.

For prospective shareholders, WOFA’s early financial growth in the thriving manufactured homes market, as well as its fully-scalable retail operations, makes the company an intriguing investment opportunity in the coming months. Look for WOFA to continue expanding its geographical reach by opening additional retail centers in the near future, providing a significant platform for sustainable financial growth moving forward.

For more information, visit www.wisdomhomesofamerica.com

Let us hear your thoughts: Wisdom Homes of America, Inc. Message Board

ENGlobal, a leading provider of engineering and automation services, today reported its financial results for the second quarter ended June 27, 2015.

Second quarter 2015 revenues totaled $21.1 million, a $6.1 million decrease from $27.2 million reported for the prior year period. Net income totaled $1 million, or $0.03 per diluted share, for the quarter ended June 27, 2015, compared to net income of $1.6 million, or $0.06 per diluted share, for the quarter ended June 28, 2014. During the quarter ended June 27, 2015, the company incurred non-cash expenses for depreciation, amortization and stock compensation of $0.5 million as compared to $0.7 million for the same period in 2014.

Mark Hess, ENGlobal’s Chief Financial Officer, stated, “We are pleased to report today’s profitable results—which I’m proud to say represents six consecutive profitable quarters. ENGlobal’s profit margins remain respectable given the current environment, and our available capital has improved over the last year. The Company continues to maintain a healthy cash balance and working capital of $25.4 million, and we have no borrowings under our current credit facility.”

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” added William Coskey, P.E., Chairman and Chief Executive Officer of ENGlobal. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

For more information on ENGlobal, visit www.englobal.com

Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The company’s product portfolio currently features five marketed treatments – including Acetadote®, Caldolor®, Kristalose®, Vaprisol® and Omeclamox-Pak® – addressing its primary target markets of hospital acute care and gastroenterology. Cumberland owns the worldwide rights to all of its brands, allowing the company to focus on the U.S. market while actively pursuing strategic partnerships and other opportunities to make its products available to patients in underserved international markets.

In the second quarter of 2015, Cumberland’s strongest performing product was Kristalose, which accounted for $4.1 million in net revenue. As the only branded prescription laxative product that features the established safety and efficacy of lactulose in a pre-measured powder dose, Kristalose offers patients a virtually tasteless, grit-free and essentially calorie-free alternative to lactulose syrups. In a 2009 study by Clinical and Experimental Gastroenterology, the company’s product was preferred by 83 percent of patients, highlighting the immense market potential of Cumberland’s product portfolio moving forward.

In addition to its commercialized products, Cumberland is currently engaged in late-stage clinical development of two promising drug candidates. Hepatoren® is being developed to treat patients suffering from hepatorenal syndrome, while Boxaban® is being developed for the treatment of aspirin-exacerbated respiratory disease. Enrollment for phase II studies of both candidates is underway and expected to be completed by the end of 2015. To ensure reliable expansion of its product portfolio in the future, Cumberland also operates Cumberland Emerging Technologies (CET), which, in collaboration with some of the country’s top universities, is providing the company with a long-term pipeline of new product candidates.

As of June 30, 2015, Cumberland reported approximately $93 million in total assets, including $53 million in cash and investments, with only $14.2 million in total liabilities. In the coming months, the company will look to leverage the flexibility offered by this balance sheet to promote long-term, sustainable growth.

“We remain in a strong financial position with a solid balance sheet and profitable operations,” A.J. Kazimi, chief executive officer of Cumberland, stated in a news release. “We are working to maximize the potential of our five commercial products and actively pursuing the addition of new brands to our portfolio.”

With an established product portfolio, a promising development pipeline and a steady supply of new candidates provided by CET, Cumberland is in a strong strategic position to expand upon its considerable industry presence in the years to come. For prospective shareholders, the company’s favorable balance sheet and persistent commitment to expanding upon its market share could foreshadow an opportunity for Cumberland to achieve sustainable returns for the foreseeable future.

For more information, visit www.cumberlandpharma.com

An estimated two billion people around the globe want to learn to speak English, providing a significant opportunity for businesses that can translate this market demand into financial returns. In 2013, the global market for language learning was estimated at more than $56 billion, and English programs accounted for a substantial portion of that spending. Lingo Media Corporation (OTCQB: LMDCF), through a combination of both online and print-based education products, is thriving in this lucrative market segment under the leadership of one of the industry’s most seasoned executive teams.

For many years, Lingo’s operations centered on a business unit that co-publishes textbook programs used in China. In 2014, this established unit reported free cash flow of about $1.5 million. However, in recent months, the company has transitioned its operations to take advantage of the rapidly expanding market for educational technology, which is currently outpacing the growth of brick-and-mortar education by a considerable margin. As a result, Lingo promptly acquired an award-winning content library, as well as two other eLearning platforms, to create one of the most diverse, customizable language learning tools on the market.

Through its proprietary eLearning software, Lingo adds a collection of revenue streams that capitalize on the strong performance of the global language-learning market. In particular, the company receives licensing fees for each new client, as well as recurring licensing fees throughout the educational experience. By partnering with a top-tier software development team, Lingo has successfully built a library that boasts thousands of lessons designed to meet the specific needs of its clients, improving the outlook of licensing revenue for the foreseeable future.

When entering new markets, Lingo utilizes an innovative business strategy to keep costs down without sacrificing on client satisfaction. Instead of opening permanent offices in each individual country, the company forms relationships with external contractors and distributors in order to market its products. This strategy allows Lingo to consistently minimize costs, giving the company an advantage over its competitors in the same markets. For prospective shareholders, these efforts promote high margins and potentially rapid growth.

In the first quarter of 2015, Lingo demonstrated the effectiveness of its unique approach to market growth by posting a 176 percent year-over-year increase in revenue, recording over $651,000 for the period. Similarly, the company recorded a net profit of more than $225,000, up from a net loss of $52,870 in the same period of the previous year. Lingo will look to build on this profitability throughout the remainder of 2015.

Moving forward, Lingo’s priority is to win new contracts and fuel revenue, earnings and cash flow in an attempt to pay off outstanding debt and finish the year with a clean balance sheet. Since small-cap growth stocks with low debt and high profit margins offer strong potential for market gains, these efforts could serve as a catalyst for rapid increases to Lingo’s market value in the months to come.

For more information, visit www.lingomedia.com

QualityStocks today announces the availability of a new audio interview with Mr. Eric Fresh, Senior Vice President of Finance and Investments for Dominovas Energy Corporation (OTCQB: DNRG). The interview can be heard at www.QualityStocks.net/interview-dnrg.php.

At the forefront of Dominovas Energy’s mission to deliver clean, efficient and reliable electricity to areas of the world that lack this valuable commodity is the Company’s proprietary technology, the RUBICON™, and its visionary leadership. Fresh begins the interview by discussing his own expertise, how it applies to the Company’s vision, and why he believes Dominovas Energy is positioned for success.

“What brought me to Dominovas Energy initially was the opportunity to work with an extraordinary executive suite. The Company’s vision to deploy its RUBICON™ system globally was indeed exceptional… I’ve worked on more than $4 billion of structured debt and equity transactions for projects all over the world. Most of those were directly related to power generation in the energy sector. Dominovas Energy, as a company, is poised and positioned for unprecedented success in the global power sector,” asserted Fresh.

Dominovas Energy is the first and only fuel cell company selected as a private sector partner to President Barack Obama’s Power Africa Initiative (PAI). Fresh describes how the Company’s partnership with Delphi Automotive Systems validates a robust supply chain in the manufacture of its solid oxide fuel cell stacks, which is the heart of the RUBICON™ system, and how its deployment fits into the broader value created to impact both domestic and foreign economies.

“Collectively, with our OEM partners, we have a significant, vested interest in the successful deployment of our RUBICON™ systems throughout sub-Saharan Africa… consider the relationship with our U.S.-based OEM partner Delphi Automotive Systems. Our relationship presents a broad-based value proposition. The engagement of Delphi secures the Company’s supply chain relative to its most critical component: the production of fuel cell stacks. This partnership affords Dominovas Energy a capability well beyond any other fuel cell company in the market,” he explains.

As further mentioned in the interview, Dominovas Energy has signed more than 200MW of guaranteed PPAs, establishing the base of production that promotes “efficient and cost-effective” manufacturing of the Company’s proprietary RUBICON™ system. Fresh notes that ongoing production and manufacturing of the system will create a hearty global supply chain and stimulate global job expansion while supporting the PAI to create greater access to electricity in sub-Saharan Africa.

Fresh also eased concerns regarding how U.S. Export Import Bank’s charter not being re-authorized impacts the financing of RUBICON™’s deployment.

“We see no immediate impact as the Company has not to date initiated any financing sequences with them. However, it is indeed unfortunate that the U.S. Ex-Im Bank’s charter has not been reauthorized, as Ex-Im has been, and is, a critical component of many U.S. companies that are engaged in international commerce.”

Dominovas Energy is however actively engaging several Power Africa Partners, both private and public, that are steadfast in their commitment relative to financing project development and deployment of RUBICON™ systems in sub-Saharan Africa. These Initiative Partners include Goldman Sachs, Barclays Africa, the Overseas Private Investment Corporation (OPIC) and Africa Development Bank (AfDB).

“Ultimately, each of the institutions that we engage are engaged specifically because they have mandates which are inclusive of being focused on deploying capital to support further development of power infrastructure projects in sub-Saharan Africa,” says Fresh.

Turning to expenses associated with deployment, Fresh provides an account of the variables that affect the costs to install power generation based upon the RUBICON™.

“The RUBICON™ is a precision engineered and highly customized next-generation technology that produces clean, reliable and sustainable electricity in global emerging markets… many of these markets lack the infrastructure for basic access to electricity, so our customizable, modular, megawatt-scaled RUBICON™ units are ideal, as there’s no reliance on antiquated legacy transmission infrastructure,” reminds Fresh.

Fresh concludes the interview by addressing what some would perceive as challenges to obtaining financing of projects in the Democratic Republic of Congo (DRC), and how the company is providing an unprecedented number of megawatts.

“Financing such a large deployment is not as much a challenge, as it is a spectacular opportunity for Dominovas Energy. The DRC is a country rich with potential. It is indeed that potential that presents an unprecedented opportunity for Dominovas Energy. Through years of cultivating relationships at the highest levels in government, we are now realizing the fruits of that labor with the prospect of adding to those resources, in a very significant way; mind you, by delivering power with attendant financial support,” says Fresh. “The Company is continually enhancing and cultivating its financial relationships along with its ability to execute in the DRC.”

Again, the interview can be heard at http://www.QualityStocks.net/interview-dnrg.php.

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

FluoroPharma Medical is a biopharmaceutical company engaged in the discovery and development of proprietary positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Currently, the company is advancing two such product candidates in clinical trials – including CardioPET and BFPet – which have been specially designed to rapidly target myocardial cells. Upon commercialization, these innovative products are expected to enable more accurate, early diagnosis of CAD, effectively facilitating improved treatment options and better patient outcomes.

The market potential for a more effective diagnostic tool for CAD is expansive. According to a report by the Centers for Disease Control and Prevention, heart disease accounts for approximately 610,000 deaths in the United States each year, making it the country’s leading cause of death. Among these fatalities, approximately 47 percent occur as a result of heart attacks outside of hospitals, suggesting that many people with CAD don’t receive proper diagnosis. FluoroPharma is addressing this issue by developing molecular imaging as a faster, more accurate approach to today’s standard test for diagnosing CAD.

CardioPET is designed to address the current limitations of CAD diagnostics. Upon commercialization, CardioPET is expected to be the first commercially-available fatty acid analog marker in the U.S. and Europe, giving FluoroPharma a noteworthy strategic advantage in the substantial diagnostic markets of the two regions. Unlike currently available tools, a traceable fatty acid analog marker will enable improved evaluation of cardiac blood flow and the dietary preference of the cardiac muscle under stress and at rest, clearly indicating the metabolic state of the heart and providing a more comprehensive assessment of CAD.

“We are encouraged by our progress to date, and believe that CardioPET potentially signals a compelling new direction for PET cardiac imaging at a time when healthcare professionals around the world could benefit from novel diagnostic imaging that expand and improve their diagnostic capabilities,” Thijs Spoor, chairman and chief executive officer of FluoroPharma, stated in a news release.

According to its most recent update, the company has completed enrollment for its phase II clinical trial of CardioPET for the assessment of CAD. This study, which is designed to assess the safety and diagnostic performance of FluoroPharma’s innovative agent, marks a significant step in the continued development of CardioPET. For prospective shareholders, the company’s sustained progress toward the commercialization of its promising development pipeline, in addition to the considerable marketability of its proprietary diagnostic tools, could foreshadow an opportunity for FluoroPharma to achieve sustainable returns in the months to come.

For more information, visit www.fluoropharma.com